A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1800 participants.

Also called NCT03970031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,800 participants (planned count) (from the registry)
Sponsor
Cirius Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT03970031
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03970031. Randomized; quadruple masking; primary purpose treatment. Start 2022-06 (anticipated); primary completion 2024-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
Condition
Type2 Diabetes
Condition
NASH - Nonalcoholic Steatohepatitis
Condition
Nonalcoholic Steatohepatitis
Condition
Non-Alcoholic Fatty Liver Disease
Intervention (Drug)
MSDC-0602K
Intervention (Drug)
Placebo
Lead sponsor
Cirius Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03970031
Content hash
3f64f18d83758f5424fab222acce834448815efc1bfb9aae6a8f13d7e009daf5